Palovarotene.
Författaruppgift saknas
Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxad229 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för palovarotene. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
26 träffarStudy methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ, Al Mukaddam M, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, Le Quan Sang KH, Grogan DR, Marino R, Strahs AR, Kaplan FS.
BMC Med Res Methodol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12874-023-02080-7Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations.
Mundy C, Yao L, Shaughnessy KA, Saunders C, Shore EM, Koyama E, Pacifici M.
JBMR Plus · research-article; journal article · DOI 10.1002/jbm4.10821The Pharmacokinetic Profile of Palovarotene: An Open-Label Phase I Trial Investigating the Effect of Food and Potential for Drug-Drug Interaction in Healthy Participants.
Marino R, Dube L, Ogier J, Le Quan Sang KH.
Eur J Drug Metab Pharmacokinet · research-article; clinical trial, phase i; journal article · DOI 10.1007/s13318-023-00856-2Palovarotene (Sohonos): CADTH Reimbursement Review: Therapeutic area: Fibrodysplasia (myositis) ossificans progressiva
Författaruppgift saknas
Tidskrift saknas · reviewPalovarotene (Sohonos): CADTH Reimbursement Recommendation: Indication: To reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia (myositis) ossificans progressiva
Författaruppgift saknas
Tidskrift saknas · reviewA Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants.
Dube L, Haga N, Grogan D, Ogier J, Le Quan Sang KH.
Eur J Drug Metab Pharmacokinet · research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s13318-023-00815-xReduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ, Hsiao EC, Al Mukaddam M, Baujat G, Berglund SK, Brown MA, Cheung AM, De Cunto C, Delai P, Haga N, Kannu P, Keen R, Le Quan Sang KH, Mancilla EE, Marino R, Strahs A, Kaplan FS.
J Bone Miner Res · research support, non-u.s. gov't; journal article · DOI 10.1002/jbmr.4762A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution.
Foster WJ, Strahs AL, Small KW, Roach JM.
Drugs R D · research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s40268-022-00410-6Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition.
Yu G, Corn PG, Shen P, Song JH, Lee YC, Lin SC, Pan J, Agarwal SK, Panaretakis T, Pacifici M, Logothetis CJ, Yu-Lee LY, Lin SH.
Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-22-0170RARγ: The Bone of Contention for Endothelial Cells in Prostate Cancer Metastasis.
Bhowmick S, Bhowmick NA.
Cancer Res · comment; editorial · DOI 10.1158/0008-5472.can-22-2251Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ, Baujat G, Hsiao EC, Keen R, Wilson A, Packman J, Strahs AL, Grogan DR, Kaplan FS.
J Bone Miner Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1002/jbmr.4655Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification.
Huang J, Wu J, Lin J, Li C, Tang B, Xiao H.
Clin Exp Pharmacol Physiol · research support, non-u.s. gov't; journal article · DOI 10.1111/1440-1681.13676A Network Pharmacology Study: Reveal the Mechanisms of Palovarotene Against Heterotopic Ossification.
Huang J, Liu D, Zhang J, Xiao H.
Front Med (Lausanne) · research-article; journal article · DOI 10.3389/fmed.2022.897392Palovarotene Can Attenuate Heterotopic Ossification Induced by Tendon Stem Cells by Downregulating the Synergistic Effects of Smad and NF-<i>κ</i>B Signaling Pathway following Stimulation of the Inflammatory Microenvironment.
Huang J, Lin J, Li C, Tang B, Xiao H.
Stem Cells Int · research-article; journal article · DOI 10.1155/2022/1560943Palovarotene: First Approval.
Hoy SM.
Drugs · review; journal article · DOI 10.1007/s40265-022-01709-zRetinoid Agonists in the Targeting of Heterotopic Ossification.
Pignolo RJ, Pacifici M.
Cells · research support, non-u.s. gov't; review-article; review; journal article; research support, n.i.h., extramural · DOI 10.3390/cells10113245Administration of a selective retinoic acid receptor-γ agonist improves neuromuscular strength in a rodent model of volumetric muscle loss.
Whitely ME, Collins PB, Iwamoto M, Wenke JC.
J Exp Orthop · research-article; journal article · DOI 10.1186/s40634-021-00378-3Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S, Kidane J, Wentworth KL, Motamedi D, Morshed S, Schober AE, Hsiao EC.
BMC Musculoskelet Disord · journal article; case reports; case-report · DOI 10.1186/s12891-020-03240-2Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
Goldhamer DJ, Lees-Shepard JB.
Elife · comment; research-article; journal article · DOI 10.7554/elife.43928Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Lees-Shepard JB, Nicholas SE, Stoessel SJ, Devarakonda PM, Schneider MJ, Yamamoto M, Goldhamer DJ.
Elife · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.7554/elife.40814Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.
Inubushi T, Lemire I, Irie F, Yamaguchi Y.
J Bone Miner Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/jbmr.3341Palovarotene inhibits connective tissue progenitor cell proliferation in a rat model of combat-related heterotopic ossification.
Wheatley BM, Cilwa KE, Dey D, Qureshi AT, Seavey JG, Tomasino AM, Sanders EM, Bova W, Boehm CA, Iwamoto M, Potter BK, Forsberg JA, Muschler GF, Davis TA.
J Orthop Res · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1002/jor.23747Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, Pacifici M, Iwamoto M, Shore EM.
J Bone Miner Res · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1002/jbmr.2820Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema.
Hind M, Stinchcombe S.
Curr Opin Investig Drugs · research support, non-u.s. gov't; review; journal articlePharmacokinetics of a novel agent, R667, in patients with emphysema.
Chiu YY, Roth MD, Kolis S, Rogovitz D, Davies B.
Br J Clin Pharmacol · research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1365-2125.2006.02808.x